Albert J. Robichaud
2020
In 2020, Albert J. Robichaud earned a total compensation of $2.1M as Chief Scientific Officer at Sage Therapeutics, a 46% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $203,405 |
|---|---|
| Option Awards | $1,173,476 |
| Salary | $442,184 |
| Stock Awards | $303,300 |
| Other | $11,543 |
| Total | $2,133,908 |
Robichaud received $1.2M in option awards, accounting for 55% of the total pay in 2020.
Robichaud also received $203.4K in non-equity incentive plan, $442.2K in salary, $303.3K in stock awards and $11.5K in other compensation.
Rankings
In 2020, Albert J. Robichaud's compensation ranked 5,221st out of 13,090 executives tracked by ExecPay. In other words, Robichaud earned more than 60.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,221 out of 13,090 | 60th |
Division Manufacturing | 2,149 out of 5,617 | 62nd |
Major group Chemicals And Allied Products | 858 out of 2,248 | 62nd |
Industry group Drugs | 739 out of 1,948 | 62nd |
Industry Pharmaceutical Preparations | 554 out of 1,453 | 62nd |
Source: SEC filing on April 29, 2021.
Robichaud's colleagues
We found five more compensation records of executives who worked with Albert J. Robichaud at Sage Therapeutics in 2020.
News
Sage Therapeutics CEO Barry Greene's 2021 pay jumps 469% to $59M
April 28, 2022
Sage Therapeutics CEO Jeffrey Jonas' 2020 pay falls 53% to $4.7M
April 29, 2021
Sage Therapeutics CEO Jeffrey Jonas' 2019 pay rises 1% to $9.9M
April 29, 2020
Sage Therapeutics CEO Jeffrey Jonas' 2018 pay jumps 71% to $9.8M
April 25, 2019